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INTRODUCTION
Background
Emergency department (ED) visits related to opioid use 
disorder (OUD) have increased nearly twofold over the last 
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Introduction: Emergency department (ED) visits related to opioid use disorder (OUD) have 
increased nearly twofold over the last decade. Treatment with buprenorphine has been 
demonstrated to decrease opioid-related overdose deaths. In this study, we aimed to better 
understand ED clinicians’ attitudes toward the initiation of buprenorphine treatment in the ED.
Methods: We performed a mixed-methods study consisting of a survey of 174 ED clinicians 
(attending physicians, residents, and physician assistants) and semi-structured interviews with 
17 attending emergency physicians at a tertiary-care academic hospital. 
Results: A total of 93 ED clinicians (53% of those contacted) completed the survey. While 
80% of respondents agreed that buprenorphine should be administered in the ED for patients 
requesting treatment, only 44% felt that they were prepared to discuss medication for addiction 
treatment. Compared to clinicians with fewer than five years of practice, those with greater 
experience were less likely to approve of ED-initiated buprenorphine. In our qualitative analysis, 
physicians had differing perspectives on the role that the ED should play in treating OUD. 
Most physicians felt that a buprenorphine-based intervention in the ED would be feasible with 
institutional support, including training opportunities, protocol support within the electronic health 
record, counseling and support staff, and a robust referral system for outpatient follow-up.
Conclusion: ED clinicians’ perception of buprenorphine varied by years of practice and training 
level. Most ED clinicians did not feel prepared to initiate buprenorphine in the ED. Qualitative 
interviews identified several addressable barriers to ED-initiated buprenorphine. [West J Emerg 
Med. 2020;21(2)261-271.]
decade.1 As a critical access point for patients with OUD, the 
ED is well positioned to provide and link patients to OUD 
treatment.2 However, current practice in United States EDs 
for patients seeking treatment for OUD is referral to addiction 
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Population Health Research Capsule
What do we already know about this issue?
Treatment of opioid use disorder (OUD) 
with buprenorphine has been shown to 
decrease opioid-related overdose deaths while 
improving retention in treatment. 
What was the research question?
How do emergency department (ED) 
clinicians perceive opioid use disorder and 
ED-initiated buprenorphine?
What was the major finding of the study?
Most ED clinicians supported ED-initiation of 
buprenorphine, which would be feasible with 
robust institutional support. 
How does this improve population health?
This study provides potential solutions to 
facilitate the initiation of buprenorphine in the 
ED and transform the delivery of emergency 
care for OUD patients.
treatment services, which often consist of abstinence-based 
programs or psychosocial interventions.3 
Buprenorphine is a first-line medication for addiction 
treatment (MAT) of OUD.4 Treatment with buprenorphine 
decreases non-medical opioid use and opioid-related overdose 
deaths while improving retention in treatment compared to 
patients receiving abstinence-based treatment or psychosocial 
intervention.5-8 A recent randomized controlled study 
demonstrated that when buprenorphine treatment was initiated 
in the ED, patients were more likely to remain engaged in 
treatment compared to brief intervention and referral for 
treatment.9 ED-initiated buprenorphine was also found to be 
cost-effective compared with referral to community-based 
treatment or combined brief intervention and referral.10 
Importance
Several EDs have launched ED-initiated treatment 
programs with buprenorphine.2,11-14 Legislative changes are 
also underway to incorporate initiation of buprenorphine 
into ED management of patients of OUD. For example, 
a new State of Massachusetts law requires acute care 
hospitals that provide emergency services to have the 
capacity to initiate opioid agonist therapy to patients 
after an opioid-related overdose, and to directly connect 
the patients to continuing treatment prior to discharge.15 
Despite the growing national momentum toward offering 
buprenorphine in the ED, little is known about ED 
clinicians’ attitudes related to this practice.16,17 To work 
toward the goal of improving care for patients with OUD in 
the ED, it will be important to better understand clinicians’ 
diverse views on and perceived barriers to the practice of 
initiating buprenorphine in the ED.  
Goals of This Investigation
The objective of this study was to better understand 
ED clinicians’ perceptions of OUD and ED-initiated 
buprenorphine treatment. This was a mixed-methods study 
consisting of a survey and in-depth qualitative interviews 
of ED clinicians. The survey phase aimed to understand 
ED clinicians’ perceptions of ED-initiated buprenorphine 
treatment, in addition to their attitudes, clinical practice, and 
self-perceived preparedness related to caring for patients 
with OUD. The goal of the qualitative interview phase was 
to explore emergency physicians’ perceptions about their 
current management options for OUD, characterize their 
opinions about ED-initiated buprenorphine, and identify 
addressable barriers to prescribing buprenorphine in the ED. 
While the survey phase focused on measuring how many ED 
clinicians have certain perceptions, the purposive, in-depth 
qualitative interviews were designed to uncover a range of 
opinions and to identify new ideas and concepts, embedded 
in real-life experiences that frame OUD treatment for 
emergency physicians. 
METHODS
We conducted a cross-sectional survey of ED clinicians 
(attending physicians, resident physicians, and physician 
assistants) and individual semi-structured interviews with 
emergency medicine (EM) attending physicians working in an 
ED at a tertiary-care academic hospital with an annual volume 
of 65,000 patients. The study was approved by the study site’s 
institutional review board.   
Survey
The sampling frame for the survey phase consisted of 
attending physicians, residents, and physician assistants (n 
= 174) from December 2017 to February 2018. A request to 
participate along with a link to the de-identified survey was 
emailed to ED clinicians. The survey was administered via 
Qualtrics (Qualtrics, Provo, Utah). ED clinicians received an 
initial request and two reminder emails and an incentive of a 
$10 gift card for survey completion. As an exploratory study, a 
sample size calculation was not performed a priori, but rather 
investigators aimed for a response rate of >50% with a goal of 
recruiting approximately 100 participants.
A previously studied survey instrument designed 
for internal medicine physicians was adapted to assess 
ED clinicians’ attitudes, exposure, clinical practice, and 
preparedness related to caring for patients with OUD on 
an 11-point Likert scale.18 Two questions were specific to 
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understanding perceptions of buprenorphine treatment and 
whether it should be initiated in the ED. Participants’ role 
and their total years of practice in EM after graduation from 
medical or physician assistant school were also recorded.  
We selected our outcomes a priori and performed the 
Kruskal-Wallis with Bonferroni adjusted pairwise Mann-
Whitney tests to determine the differences in the responses 
based on years of practice and roles. Seven participants with 
missing responses were removed from data analysis. We used 
Stata version 13.1 (Stata Corporation, College Station, TX) for 
all statistical analyses. 
Qualitative Interview 
For the interview phase of the study, we contacted all 
ED attending physicians (n = 72 by email), informed them of 
the study, and invited them to be interviewed on a voluntary 
basis in February-March, 2018. Participants were offered a 
$50 gift card. Study participants were recruited until thematic 
saturation was reached, which is the point at which no new 
themes emerged. We recruited 17 attending physicians to 
interviews, in line with typical sample size employed to 
achieve thematic saturation in qualitative studies.19 
Qualitative, semi-structured interviews were conducted 
individually in person by a research assistant (H.V.) trained in 
in-depth interviewing by an expert in qualitative methodology 
(A.C.). Informed consent was verbally obtained before 
each interview. Interview questions focused on emergency 
physicians’ experiences treating patients with OUD as well as 
attitudes towards buprenorphine initiation in the ED (Table 
1). Basic demographic information was collected about each 
participant’s number of years of practice, average number of 
shifts worked per month, and fellowship training. 
All interviews were recorded, de-identified and 
professionally transcribed. Investigators developed a 
codebook based on preliminary review of six transcripts. 
Subsequently, individual interviews were coded independently 
by four investigators (D.I., A.C., L.V., and L.C.), with NVivo 
version 12 (QSR International, Melbourne, Australia). D.I., 
A.C., and H.V. serially reviewed coded transcripts and 
discussed discrepancies until reaching consensus. Themes 
were identified using a modified grounded theory approach, 
and thematic saturation was determined by team consensus.  
RESULTS
Survey Results
Of the 100 survey respondents, 93 had complete responses 
(57% response rate, 53% completion rate) and were included 
for analysis. Table 2 summarizes the characteristics of survey 
respondents. Of the respondents surveyed, 88% agreed that 
buprenorphine should be administered in the ED for patients 
requesting treatment for OUD. However, only 44% of ED 
clinicians reported that they felt prepared to discuss MAT 
options with patients. Table 3 summarizes ED clinicians’ 
attitudes related to OUD and buprenorphine by years of practice 
and roles in the ED. Compared to clinicians with more than five 
years of practice, those with fewer years of practice were (1) 
more likely to believe that OUD is like other chronic diseases; 
(2) more likely to approve of ED-initiated buprenorphine; 
and (3) less likely to believe that buprenorphine replaces 
one addiction with another (p<0.01 for each). Compared to 
attending physicians, residents were less likely to believe that 
OUD is different from other chronic diseases (p<0.03). 
Attending physicians and residents viewed ED-initiated 
buprenorphine more favorably than physician assistants 
Domains Sample questions
Perceptions of current ED-based practices to manage patients 
seeking treatment for OUD
• Can you tell me about your experiences working with OUD 
patients? 
• How do you feel about your current personal practice when 
treating patients with OUD?
Perceptions of ED-initiated buprenorphine to treat OUD • What are your thoughts on ED clinicians prescribing 
buprenorphine in the ED? 
• How do you think your colleagues might feel about an ED-
based buprenorphine intervention?
Perceived barriers to initiating buprenorphine treatment in the ED • Do you think it would be practical to initiate buprenorphine in 
the ED? Why or why not?
• Tell me about your comfort level with initiating buprenorphine 
in the ED.
Potential solutions to the identified barriers • What would help facilitate you incorporating buprenorphine 
into your ED practice.
Table 1. Interview guide domains and sample questions.
OUD, opioid use disorder.
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(p<0.01). Compared to physician assistants, residents were 
also less likely to view buprenorphine as replacing one 
addiction with another (p<0.01). Compared to clinicians with 
fewer than five years of practice, those with more years of 
practice were more likely to feel prepared to discuss overdose 
prevention and naloxone with patients (p<0.03) (Table 4). 
Attending physicians were more likely to feel prepared to 
discuss harm reduction with patients than residents (p=0.01). 
Qualitative Interview Results 
Table 5 summarizes the characteristics of the 17 
interviewees. Several themes emerged regarding the 
following: (1) emergency physicians’ views of current ED 
practices to manage OUD; (2) perceptions of ED induction 
of buprenorphine for OUD treatment; (3) clinician-level 
barriers and solutions to initiating buprenorphine in the ED; 
and (4) systems-level barriers and solutions to initiating 
buprenorphine in the ED. 
Current ED-based Approaches to Manage Patients 
Seeking Treatment for OUD
The majority of the emergency physicians (EPs) 
described current practices as consulting social work (if 
available) and providing a list of detoxification facilities 
to patients. As one participant observed, “My practice has 
been pretty much what emergency physicians have largely 
done, which is I give them the badly photocopied list of 
treatment options and let them walk out the door.” 
EPs expressed frustration, anger, helplessness, sadness, 
and dissatisfaction when describing their current practices 
to manage patients seeking treatment for OUD in the ED 
setting. Their emotions stemmed from the inadequate and 
limited nature of the current management options. One 
emergency physician summarized: “It’s really frustrating, 
and I feel kind of helpless sometimes – where we’re doing 
the bare minimum to get them discharged, and that’s kind of 
the best we can do, and the rest of it’s on them.” Many of the 
participants associated their dissatisfaction with the sentiment 
of “temporizing things without feeling like we’re actually 
making a meaningful difference” in patients’ lives. 
Emergency Physicians’ Views of ED-initiated 
Buprenorphine Treatment
EPs expressed their view of buprenorphine as an effective 
treatment option for OUD. As one participant elaborated, “I’ve 
heard that when well managed and when well coordinated, 
that it has a whole lot better efficacy than some of the other 
things that we have seen, certainly compared to the non-
medication-assisted therapies.”
Despite favorable views of buprenorphine in general, 
only a minority of the interviewees were in favor of ED-
initiated buprenorphine. Those who supported ED-initiated 
buprenorphine often cited the duty of EM as a medical 
specialty to improve public health. One EP described EM as 
an all-encompassing specialty, with the ED serving as a point 
of capture for underserved populations: “When [patients] are 
[in the ED] for whatever issue, whether it be an overdose or 
some other medical process, it’d be a great way to capture 
them and put them into some sort of system at least to get 
[the treatment] started.”
Reluctance to support ED-based buprenorphine treatment 
stemmed from three major concerns. First, interviewees 
viewed prescribing buprenorphine as not within the scope 
of EM practice. One participant described the current ED 
practice of deferring long-term management of chronic 
illnesses to outpatient clinicians, and applied this to using 
buprenorphine to treat OUD: “My impression is that it’s 
not necessarily a great thing for emergency physicians to 
be primarily involved with those patients because – just 
like I don’t manage people’s diabetes long term and I don’t 
manage their blood pressure long term, I don’t see long-term 
management of the buprenorphine as within our wheelhouse.”
A second concern about prescribing buprenorphine related 
to patients’ potential misuse of the medication.  Interview 
participants expressed belief that buprenorphine is a highly 
diverted medication, which would encourage patients to 
either abuse or sell ED-prescribed buprenorphine. One 
physician stated, “What I do fear is that there is a potential 
for emergency medicine to be seen as like a way to potentiate 
kind of bad habits if people know like ‘oh, if I go and I ask for 
buprenorphine, I’ll get a script for it and I can somehow misuse 
that.’ That’s one of my concerns. I know buprenorphine has 
some kind of misuse prevention kind of built into the way it’s 
formulated, but I still think it’s sold on the street and has a street 
value and is – it could be misused. I just want to be careful that 
I’m not adding to the problem and that I really am alleviating 
the problem by me participating in this way.”
n %
Gender
Male 48 51.6%
Female 45 48.4%
Role
Attending 26 28.0%
Resident 41 44.0%
Physician Assistant 26 28.0%
Years of Practice
0-5 years 55 59.1%
6-10 years 18 19.4%
>10 years 20 21.5%
Table 2. Demographics of survey respondents.
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Median Response (IQR)
Years of Practice Roles
Perception of OUD All clinicians < 5 years ≥ 5 years P value Attg EP Resident EP PA P value
Opioid use disorder (OUD) is 
different from other chronic 
diseases (e.g., diabetes, 
hypertension) because 
people who use drugs like 
heroin or illicit opioids are 
making a choice. 
3
(2-6)
2.5
(1-5)
4
(2-7)
<0.01 5
(3-7)
3
(1-4)
2.5
(1-5)
<0.03α
Opioid use disorder is a 
treatable disease.
8 
(7-10)
8 
(7-10)
8 
(6-10)
0.66 8 
(6-10)
8 
(7-10)
8 
(7-10)
0.85
I find caring for patients 
with opioid use disorder 
as satisfying as my other 
clinical activities. 
3 
(2-5)
3.5 
(2-5)
3 
(2-5)
0.84 3 
(1-5)
4 
(2-5)
3 
(2-7)
0.59
Treating opioid use disorders 
reduces associated health 
and social costs by more than 
the cost of the treatment itself. 
8 
(7-10)
8 
(7-10)
9 
(7-10)
0.98 9 
(7-10)
8 
(8-10)
8 
(7-10)
0.59
Patients with opioid 
use disorder are more 
challenging to take care of 
than the average patient. 
7 
(7-0)
7 
(7-9)
8 
(7-10)
0.01 8 
(7-10)
7 
(7-9)
8 
(7-10)
0.21
Someone who uses drugs 
is committing a crime and 
deserves to be punished.
1 
(0-3)
1 
(0-3)
1 
(0-3)
0.63 1 
(0-3)
1 
(0-3)
1 
(0-2)
0.55
Perception of
Buprenorphine Treatment
I think buprenorphine should 
be administered in the ED for 
patients requesting treatment 
for OUD (with referral 
for outpatient long-term 
buprenorphine management)?
7 
(5-9)
8 
(6-10)
6 
(3-9)
<0.01 7 
(4-9)
9 
(7-10)
5 
(2-6)
<0.01βΔ
Using medications like 
methadone and buprenorphine 
for opioid use disorder is 
simply replacing one addiction 
with another.
1
(1-4)
1 
(0-3)
3 
(1-6)
<0.01 2 
(1-4)
1 
(0-3)
3 
(1-6)
<0.01Δ
αstatistically significant difference between attending EP and resident EP.
βstatistically significant difference between attending EP and PA.
Δstatistically significant difference between resident EP and PA.
IQR, interquartile range; Attg, attending; EP, emergency physician; PA, physician assistant.
Table 3. Attitudes towards opioid use disorder (OUD) and buprenorphine treatment by years of practice and roles. Eleven discrete, 
graded responses were possible for each question, with a score of 10 indicating strongly agree and 0 indicating strongly disagree.
Third, physicians vocalized their concerns about 
inadvertently harming patients with buprenorphine. They 
expressed reluctance to start prescribing a new medication that 
could result in overdose or co-ingestion with other sedatives, 
such as benzodiazepines. Another physician offered, “If they 
take higher than normal doses to get an effect and you end up 
causing a death or an inadvertent overdose because of the way 
it’s done and the mechanism of action and somebody wants to, 
you end up doing more harm.”
Clinician-level Barriers and Solutions to Provision of MAT 
in the ED  
EPs also identified three major clinician-level addressable 
barriers potential and solutions. First, EPs commonly cited 
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that the current length of the waiver training is burdensome. 
Under the Drug Addiction Treatment Act of 2000 (DATA 
2000), physicians are required to complete an eight-hour 
training to qualify for a waiver to prescribe and dispense 
buprenorphine.20 As a potential solution, participants 
suggested providing financial or academic incentives for 
completing the waiver training. In addition to the waiver 
training required for potential prescribers, an institution-
wide educational campaign was recommended for other 
stakeholders in the ED, including nurses, non-physician 
clinicians, administrative staff, and other support staff. As 
one participant stated, “I just think there would have to be an 
emergency department-wide educational process. The nurses 
need to be on board. The whole team needs to be on board.”  
A second barrier noted was the time-consuming nature 
of building therapeutic relationships in order to identify ideal 
candidates for buprenorphine treatment and to engage these 
patients for buprenorphine induction in the ED. As one EP 
expressed, “It’s unrealistic for the ER doc to do that because 
it takes time.” Another commented about resource utilization: 
“The reality is it’s time away from other patients.” One 
participant made an analogy to providing medical forensic 
care to victims of sexual assault or abuse, stating that it is 
a skillset she has acquired in her training, but has not used 
frequently enough to feel confident in her ability to conduct 
an exam efficiently, effectively, and safely. She advocated 
that just as specialized practitioners, such as a sexual assault 
nurse examiner, are better equipped with training, practice, 
and time to conduct an exam for forensic evidence collection, 
EDs should employ dedicated, specialized staff (social worker, 
advocate, or addiction specialist) to identify patients ideal for 
ED-initiation of buprenorphine, to discuss instructions on how 
to start buprenorphine, and to ensure outpatient follow-up. 
A third clinician-level barrier identified was a reported 
lack of motivation to start patients on buprenorphine in the 
ED because of delayed clinical gratification. Participants 
expressed frustration with the inability to see the impact of 
engaging patients to start MAT in the ED on long-term opiate 
use. One potential solution offered was to create a mechanism 
that tracks patients’ engagement in outpatient MAT after 
ED discharge and reports it back to ED prescribers. As one 
participant stated, “[it] would be really key to be able to show 
Table 4. Summary response of current practice (A) and preparedness to care for patients with opioid use disorder (OUD) (B) by years 
of practice and roles. Eleven discrete, graded responses were possible for each question, with a score of 10 indicating very frequently/
very prepared and 0 indicating very infrequently/very unprepared.
Median Response (IQR)
Years of Practice Roles
All clinicians < 5 years ≥ 5 years P value Attg EP Resident EP PA P value
Current Practice
See a patient who asks 
for help with OUD 
5 (3-8) 5.5 (2-8) 5 (3-8) 0.87 5.5 (3-7) 5 (5-7) 6 (2-8) 0.70
Refer a patient to 
OUD treatment
5 (2-6) 3.5 (1-6) 5 (2-7) 0.22 5 (2-7) 4 (2-6) 5 (2-7) 0.44
Prescribe naloxone 2 (1-6) 2.5 (1-6) 2 (1-7) 0.86 3 (0-7) 3 (1-6) 2 (2-7) 0.99
Preparedness 
Screen for OUD 7 (5-8) 6 (5-8) 7 (5-9) 0.10 8 (4-9) 6 (5-8) 7 (5-9) 0.41
Diagnose OUD 7 (6-8) 7 (6-8) 7 (5-8) 0.82 8 (6-8) 7 (6-8) 6 (5-8) 0.50
Provide brief intervention 6 (3-8) 5 (3-7) 7 (4-8) 0.06 5 (4-8) 5 (3-7) 7 (5-8) <0.01Δ
Refer to OUD treatment 6 (3-8) 7 (4-8) 6 (3-8) 0.48 5 (2-7) 7 (4-8) 7 (3-8) 0.15
Discuss behavioral 
therapy
3 (2-6) 3 (2-6) 4 (2-6) 0.29 3.5 (2-7) 3 (1-5) 4 (3-6) 0.10
Discuss medication 
OUD treatment
4 (2-6) 5 (2-6) 3 (2-6) 0.25 4 (2-6) 4 (2-6) 3 (2-6) 0.90
Discuss overdose 
prevention and naloxone
8 (6-9) 7 (6-9) 8 (7-10) <0.03 8 (6-10) 7 (5-9) 9 (8-10) <0.01Δ
Discuss harm reduction 7 (5-8) 7 (5-8) 7 (5-9) 0.12 7.5 (5-9) 6 (5-7) 7.5 (5-9) <0.02α
αstatistically significant difference between attending EP and resident EP.
βstatistically significant difference between attending EP and PA.
Δstatistically significant difference between resident EP and PA.
OUD, opioid use disorder; IQR, interquartile range; Attg, attending; EP, emergency physician; PA, physician assistant.
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n %
Gender
Male 11 64.7%
Female 6 35.3%
Fellowship Training
Completed 8 47.1%
Not completed 9 52.9%
Current Practice Setting
Academic ED only 8 47.1%
Academic ED and community ED 9 52.9%
Years of Practice
0-5 years 4 23.5%
6-10 years 2 11.8%
>10 years 11 64.7%
Median 12 (IQR 9-20)
IQR, interquartile range; ED, emergency department.
Table 5. Demographics of interviewees.
that this was having positive outcomes for people and I think 
that kind of positive feedback would be really helpful.” See 
Table 6 for additional supporting quotes. 
System-level Barriers and Solutions to Provision of MAT 
in the ED  
Interviewees described three major systems-level barriers 
and solutions to offering buprenorphine in the ED and their 
potential solutions. First, EPs expressed discomfort with 
prescribing buprenorphine in the ED without the ability 
to ensure outpatient follow-up. In describing the need for 
establishing a long-term plan for patients being considered 
for buprenorphine, interviewees identified the anticipated 
gaps in the outpatient follow-up system. One EP questioned, 
“Like, what if the person can’t [see] the PCP for 20 days? 
Then, all of a sudden, you’re the one prescribing 20 days of 
[buprenorphine/naloxone], which – I don’t know – I might 
feel uncomfortable doing that with that patient population. 
So, I think it would have to be some sort of strict process of 
like, we’ll give you two doses or something like that, and then 
[connect them to] a good follow-up system to go to somebody 
who’s going to do it long term. Because I think that’s the issue 
with a lot of ED clinicians is we’re not going to be the ones 
following them.”
As a potential solution, EPs looked to the system-level 
approach of using electronic health record (EHR) integration for 
providing cohesive addiction treatment. EHR integration can 
enhance the ability to place electronic orders for referrals and 
to track patients using mechanisms such as a prescription drug 
monitoring program. Individualized care plans, which many 
EHRs have integrated for complex care patients, were also 
recommended to guide ED management of patients with OUD. 
Participants raised a second systems-level barrier 
of possible financial barriers for patients to continue on 
buprenorphine after ED-induction. Interviewees suggested 
that variability in insurance coverage may prohibit patients 
from continuing on buprenorphine after induction in the ED. 
In addition to having dedicated ED staff helping patients 
navigate the healthcare system and ensuring follow-up, 
physicians suggested providing ready-to-go buprenorphine in 
supply kits (3-7 days) or in a depot form. Physicians suggested 
this would ensure that patients would have the needed 
supply until they can be seen by an outpatient clinician and 
potentially minimize diversion risks.  
A third system-level barrier was the anticipated increase 
in ED volume related to patients requesting OUD treatment. 
Some physicians expressed concerns about MAT workload 
being shifted to EPs from outpatient clinicians. While some 
participants worried about the potential strain on the ED, others 
were optimistic about an eventual decrease in the number of 
ED visits related to overdoses and injuries associated with 
OUD. Physicians suggested a potential solution for reducing the 
burden on EPs was to institutionalize clear clinical protocols for 
initiating buprenorphine in the ED. Clinical protocols similar to 
those that exist for risk stratifying and managing patients with 
chest pain could be developed for initiation of buprenorphine 
in the ED for patients with OUD. Additional quotes regarding 
these themes are available in Table 7.
DISCUSSION
Our mixed-methods approach allowed a nuanced analysis 
of ED clinicians’ attitudes toward OUD and ED-initiation of 
buprenorphine for OUD treatment. Recent evidence suggests 
that ED attending physicians and residents view patients with 
substance use disorders differently than those with other medical 
conditions.17 Similarly, our data showed that some ED clinicians 
viewed OUD as different from other chronic disease, but this 
group represented only a minority of our surveyed ED clinicians 
(34% of surveyed attending physicians, residents, and physician 
assistants). Interestingly, our in-depth qualitative interviews with 
attending physicians revealed nuances in the negative emotions 
such as helplessness, sadness, and frustration associated with 
OUD and the currently limited ED-based treatment options 
for OUD. These feelings were directed at clinicians’ own 
inability to effectively help patients with OUD, and did not 
seem to be directed at the patient population itself. Unlike other 
studies that have shown health professionals’ general negative 
attitudes toward patients with OUD, we differentiate clinicians’ 
frustrations at the status quo from their negative feelings toward 
working with this patient population.16,17,22,23 These data can 
inform development of future initiatives to redesign care for 
patients requesting treatment for OUD. 
Our analysis of the survey results captured another nuance 
in ED clinicians’ attitudes toward OUD and buprenorphine: 
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Barriers Solutions
Clinician-level 1. Length of training to prescribe buprenorphine
“That’s a little bit ludicrous. I mean, I have much more 
dangerous drugs that I don’t get 10 hours of training on 
that I can read about, I can go to a lecture, I can learn 
about probably – and again, I could be wrong. This 
could be a very complicated drug, although I don’t think 
it is. Why are they putting barriers in front of the care 
providers? You know, be safe. Don’t just say, here, give 
this medication. People should know about it. But eight 
hours for one medicine that treats one disorder? That’s a 
little bit harsh.”
1. Providing training incentives and streamlining process 
for training, which includes all members of ED team
“I think if this is a hospital or institution-wide initiative, I 
think getting compensated for the time I spend getting 
the additional training to be able to write for the script, 
as well as any kind of licensing costs paid for by the 
hospital would be I think a nice sign or it’s a signal from 
the hospital of the importance of this issue and the 
support that they’re willing to give for this.”
2. Time-consuming nature of building therapeutic 
relationships and initiating buprenorphine
“What’s that like? How long does it take? Is it like a mental 
health office visit where you sit down and counsel them for 
45 minutes? If that’s what’s involved with this stuff, then I 
can imagine that nobody’s got time for that.”
2. Dedicating staff for identifying patients and initiating 
buprenorphine in the ED
“If you could do all of that, you have like a dedicated 
– like a SWAT team that came down, like an addiction 
team, identify this patient, do all that, figure out, is this 
an appropriate patient to prescribe buprenorphine?”
3. Lack of immediate impact on patients
“... to take time [initiating buprenorphine in the ED]... 
then the outcome is not immediate. And then my 
gratification for it is prolonged. That’s why I may not 
feel as that – it’s not – so, that’s the downside of doing 
something like this in the emergency department. You 
don’t see the immediate outcome. And then you’re like, 
oh, why do I have to do this?”
3. Creating a rapid feedback system to highlight the impact 
of ED-initiated buprenorphine treatment on patients
“People like me, if you ask me to do something and it’s 
all really evidence based and it’s the great thing to do 
for the patient but if I don’t get the personal feedback on 
what I did actually made a difference for that patient, it’s 
less likely for me to continue doing it even though I know 
in research papers it’s been efficacious.”
Table 6. Clinician-level barriers to emergency department-initiated buprenorphine and potential solutions with supporting quotes.
the minority of ED clinicians who negatively viewed OUD 
and ED-initiated buprenorphine had a disproportionate 
representation of clinicians with more experience. Similar 
patterns existed in the attitudes toward buprenorphine and 
its administration in the ED among survey respondents. The 
difference in the attitudes toward OUD and buprenorphine by 
years of practice may reflect changing attitudes toward OUD 
and a higher number of negative experiences associated with 
providing treatment for patients with OUD over time. We also 
attribute this difference to the increased education about OUD 
for more recently trained ED clinicians with the increased 
public awareness of the opioid epidemic, particularly 
regarding the second and third waves of rapid rise in overdose 
deaths in 2010 and 2013, involving heroin and synthetic 
opioids, respectively.24,25 
We also found a difference in the attitudes toward 
ED-initiated buprenorphine between EPs (attendings 
and residents) and physician assistants. Institution-wide 
initiatives for ED-initiation of buprenorphine must take into 
account the important roles that non-physician clinicians can 
play, with physician assistants and nurse practitioners also 
qualified to prescribe buprenorphine after obtaining a waiver. 
Notably, the Comprehensive Addiction and Recovery Act 
signed into law in 2016 requires qualifying non-physician 
clinicians to complete 24 hours of training to be eligible for 
a waiver, compared to eight hours for physicians.26 
While 80% of our survey respondents supported ED-
initiation of buprenorphine, less than half expressed comfort 
even with discussing MAT options with patients, let alone 
initiating MAT in the ED. Our findings regarding clinicians’ 
preparedness are similar to the results of a recent survey 
study: a minority of EPs felt prepared to connect patients 
with OUD to outpatient care or to initiate buprenorphine.27 
Our qualitative interviews further elucidated why ED 
clinicians feel underprepared and reluctant to treat patients 
with buprenorphine in the ED. Our interviews confirmed 
that EPs were reluctant to initiate buprenorphine despite 
their understanding of the scientific evidence behind the 
effectiveness of buprenorphine. Their reluctance originated 
from presumed unintended consequences, including 
diversion, abuse, and accidental overdoses. These concerns 
represent a double standard applied to buprenorphine, 
compared to other dangerous medications commonly 
prescribed by EPs without any special training or waivers. 
To dispel these concerns, we recommend describing the 
required Drug Enforcement Administration waiver course as 
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Barriers Solutions
System-level 1. Lack of follow-up mechanism or warm hand-off.
“I mean, for what the resources are, I feel like it’s fine. 
But it’s definitely not sufficient. When we have somebody 
who’s diabetic and comes in with high blood sugar, either 
they need to go back to see their PCP or we even have 
a program where we can get them seen in the endocrine 
clinic within the next 48 hours. Like, we really – we have 
things in place to not let those kinds of patients fall through 
the cracks. But with opioid and substance abuse disorders, 
there’s all sorts of falling through the cracks.”
1. Ensuring electronic health record integration that 
include ordering referrals, checking past prescriptions, 
and sharing individualized care plans.
“Like a medical record that we could tap in or [see] 
patterns of use, not just opiate use but of healthcare 
system use – if I could see all that, I would feel better, I 
think. Then I get a better sense of how the patient’s used 
the healthcare system and how accessible it is to them 
and how tight the safety net is with them.”
“We do have treatment plans for chronic plan that 
are really effective. We have patient populations, like 
for example, sickle cell patients with vaso-occlusive 
crisis. So it could be very much like that [for patients on 
buprenorphine] – an individualized plan.”
2. Affordability of buprenorphine and pitfalls in 
payment models.
“Is there an insurance issue? [Patients] could be the 
ideal candidate, but [if] they don’t have insurance or 
their insurance doesn’t cover it, [they will be] paying 
out-of-pocket. Or then they can’t get to the clinic or they 
can’t get follow-up. Yeah, the healthcare system is tough 
to navigate sometimes.”
2. Providing ready-to-go buprenorphine supply or in a 
depot form.
“But if we had ready-made, one-week supplies or 
three-day supplies, I think that would increase the 
likelihood that patients actually were able to access it 
and take it appropriately.”
“If there was a longer term and non-divertible, like a 
depo shot for example or something like that, I think that 
would be ideal just because it – you know that they’re 
going to receive it. They’re not going to divert it.”
3. Likely increase in patient volume.
“I fear if that word gets out, then we see a 15 percent 
rise in ED visits for, please give me buprenorphine, 
which I don’t think we want. I think what we really would 
like to see is that this becomes a more ubiquitous 
treatment as an outpatient so we actually see fewer of 
these patients in overdose in the ED. I worry about the 
buprenorphine-prescribing workload being shifted to 
emergency physicians.”
3. Institutionalizing clear protocols for ED-initiation 
of buprenorphine.
“We have pathways for atrial fibrillation, starting blood 
thinners, and that’s like really well thought out, and most 
people have no problem with that. I think it would be a 
similar thing with buprenorphine. But, I think people just 
need assurance that it’s not unsafe for the patient and for 
themselves, like medically and legally.”
Table 7. System-level barriers to emergency department-initiated buprenorphine and potential solutions with supporting quotes.
PCP, primary care physician; ED, emergency department.
a tool that empowers EPs with new knowledge and skillsets 
to transform addiction care—akin to mastering techniques 
for nerve blocks and difficulty airways. 
Our preliminary study identified a mix of barriers to ED-
initiated buprenorphine at the clinician and system levels, but 
all the suggested solutions were beyond what one clinician 
could do, highlighting the need for institutional support. 
EPs supported integrated healthcare delivery systems that 
seamlessly coordinate care between the ED and outpatient 
providers with central databases that allow creation and 
visualization of complex care plans and prior prescriptions. 
As managed care becomes increasingly pervasive 
in healthcare for both privately and publicly insured 
individuals, we anticipate more healthcare organizations will 
be incentivized to implement initiatives that coordinate care 
for chronic, complex conditions such as OUD. Managed care 
organizations aligning payment incentives with performance 
goals present opportunities for EM as a specialty to advocate 
for integrating care to support ED-initiated buprenorphine 
programs. Building on this preliminary study results, future 
research can include a larger sample from EDs across the 
spectrum (academic, community, urban, and rural) to gather 
more generalizable results. Future directions also include 
implementation of our suggested clinician- and systems-level 
solutions and analysis of the impact of the interventions on 
initiating buprenorphine in the ED. 
LIMITATIONS
Our study is limited by the small sample size, which 
may influence the generalizability of the results. Second, 
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our survey study had a low response rate (53% completion 
rate), which may have contributed to sampling bias. Those 
who responded to survey and interview invitations may have 
chosen to participate due to interests in OUD not present in 
the general population of participating physicians. Third, our 
study took place in Massachusetts, which is one of the states 
most affected by the opioid epidemic.21 Clinicians in this 
practice setting have significant exposure to MAT strategies, 
and acceptability of buprenorphine may reflect regional 
emphasis on this issue. At the time of the study, another 
hospital in our health system initiated a program to encourage 
ED attending physicians to become waivered to prescribe 
buprenorphine. Our study participants’ exposure to this 
program within the same health system may have affected the 
external validity of our findings. The geographic limits may 
also impact the generalizability of the results. 
Fourth, our study relied on clinicians whose primary 
appointment is at an ED at a tertiary-care academic hospital, 
which is more likely to be equipped with addictions 
counseling resources and to be associated with more outpatient 
buprenorphine prescribers compared to the community ED 
setting. While all of the residents and physician assistants 
surveyed also work in surrounding community EDs, just half 
of the attending physicians interviewed reported that they also 
have additional appointments in addition to the academic ED 
where the study took place. This may have biased our study 
participants in their views on feasibility of initiating treatment 
with buprenorphine, thus limiting the generalizability of the 
study results. The survey results may not be representative of 
the perception of general EPs due to the inclusion of residents, 
whose external clinical exposure is largely defined by the 
residency program leadership and the training site. In addition, 
our reliance on interview-based accounts of practice may 
result in social acceptability bias, which may have limited 
participants’ honest description of their perceptions of OUD 
and buprenorphine. 
CONCLUSION
Our quantitative and qualitative data showed that 
the majority of ED clinicians neither blame patients with 
OUD for the difficulty of managing this complex, chronic 
disease nor consider OUD in and of itself different from 
other medical conditions. Although they understand the 
scientific evidence supporting buprenorphine as a long-
term treatment option for OUD, they overwhelmingly 
feel that they do not have adequate training or resources 
to initiate buprenorphine in the ED. Our qualitative 
interviews identified a need for institutional response 
and support, as well as better facilitation of training for 
waivers and coordination of follow-up after ED-initiation 
of buprenorphine. 
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